Diagnostic performance of ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography in anorectal melanoma

Abstract

To evaluate the diagnostic role of ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) in initial staging and restaging of anorectal melanoma. This was a single-institution, retrospective observational study; patients for initial staging and with clinical or radiological suspicion of disease recurrence referred for PET/CT between January 2006 and December 2015 were included in the study. Diagnostic performance of PET/CT was evaluated for baseline staging and disease recurrence. A total of 61 patients who were referred for initial staging were included. PET/CT correctly detected primary lesion in 57 (93.44%) cases, regional nodes in 46 (75.4%) cases, nonregional nodes in 22 (36%) cases, and distant metastases in 25 (41%) cases. The sensitivity (SN); specificity (SP); positive predictive value (PPV); negative predictive value (NPV); and accuracy for primary lesion, regional nodes, nonregional nodes, and distant metastases were 96.6%, 100%, 100%, 50%, and 96.7%; 97.9%, 100%, 100%, 93.3%, and 98.4%; 100%, 100%, 100%, 100%, and 100%; and 100%, 100%, 100%, 100%, and 100%, respectively. A total of 24 patients were included for suspected recurrence/restaging. All the patients were treated previously by surgery, radiotherapy, or chemotherapy. PET/CT detected disease recurrence in 20 (83.3%) patients. Ten patients had recurrence at the primary site, 8 of whom also had distant metastases and 2 had only locoregional metastatic nodes. In the remaining 10 patients, there was no primary site recurrence; however, 2 patients had locoregional nodal and distant metastases and 8 patients had only distant metastases. PET/CT was false negative in 1 patient, which missed liver metastasis. SN, SP, PPV, and NPV of PET/CT was found to be 95%, 100%, 100%, and 75%, respectively, with accuracy of 96%. PET/CT demonstrates overall high diagnostic accuracy in the initial staging and detection of recurrent disease in cases of anorectal melanoma.

Keywords

Accuracy - anorectal - diagnostic - melanoma - positron emission tomography/computed tomography

Financial support and sponsorship

Nil.

Publikationsverlauf

Eingereicht: 21. November 2020

Angenommen: 03. Dezember 2020

Artikel online veröffentlicht:
24. März 2022

• References

• 1 Stefanou A, Nalamati SP. Anorectal Melanoma. Clin Colon Rectal Surg 2011;24:171-6.
• 2 Row D, Weiser MR. Anorectal melanoma. Clin Colon Rectal Surg 2009;22:120-6.
• 3 Singer M, Mutch MG. Anal melanoma. Clin Colon Rectal Surg 2006;19:78-87.
• 4 Meguerditchian AN, Meterissian SH, Dunn KB. Anorectal melanoma: Diagnosis and treatment. Dis Colon Rectum 2011;54:638-44.
• 5 Gilchrest BA, Eller MS, Geller AC, Yaar M. The pathogenesis of melanoma induced by ultraviolet radiation. N Engl J Med 1999;340:1341-8.
• 6 Siegal B, Cohen D, Jacob ET. Surgical treatment of anorectal melanomas. Am J Surg 1983;146:336-8.
• 7 Pessaux P, Pocard M, Elias D, Duvillard P, Avril MF, Zimmerman P, et al. Surgical management of primary anorectal melanoma. Br J Surg 2004;91:1183-7.
• 8 Ben-Izhak O, Bar-Chana M, Sussman L, Dobiner V, Sandbank J, Cagnano M, et al. Ki67 antigen and PCNA proliferation markers predict survival in anorectal malignant melanoma. Histopathology 2002;41:519-25.
• 9 Falch C, Mueller S, Kirschniak A, Braun M, Koenigsrainer A, Klumpp B. Anorectal malignant melanoma: curative abdominoperineal resection: patient selection with ¹⁸F-FDG-PET/CT. World J Surg Oncol. 2016 Jul 15;14:185.
• 10 O'Regan K, Breen M, Ramaiya N, Jagannathan J, DiPiro PJ, Hodi FS, et al. Metastatic mucosal melanoma: Imaging patterns of metastasis and recurrence. Cancer Imaging 2013;13:626-32.
• 11 Khan M, Bucher N, Elhassan A, Barbaryan A, Ali AM, Hussain N, et al. Primary anorectal melanoma. Case Rep Oncol 2014;7:164-70.
• 12 Li ZG, Qin XJ. Primary anorectal melanoma on FDG PET/CT. Clin Nucl Med 2014;39:762-4.
• 13 Pirenne Y, Bouckaert W, Vangertruyden G. Rectal melanoma – A rare tumour. Acta Chir Belg 2008;108:756-8.
• 14 Pfannenberg C, Aschoff P, Schanz S, Eschmann SM, Plathow C, Eigentler TK, et al. Prospective comparison of ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. Eur J Cancer 2007;43:557-64.
• 15 Schuüle SC, Eigentler TK, Garbe C, la Fougère C, Nikolaou K, Pfannenberg C. Influence of (18) FFDG PET/CT on therapy management in patients with stage III/IV malignant melanoma. Eur J Nucl Med Mol Imaging 2016;43:482-8.
• 16 Reinhardt MJ, Joe AY, Jaeger U, Huber A, Matthies A, Bucerius J, et al. Diagnostic performance of whole body dual modality ¹⁸F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: Experience with 250 consecutive patients. J Clin Oncol 2006;24:1178-87.
• 17 Gao G, Gong B, Shen W. Meta-analysis of the additional value of integrated 18FDG PET-CT for tumor distant metastasis staging: Comparison with 18FDG PET alone and CT alone. Surg Oncol 2013;22:195-200.
• 18 Schwimmer J, Essner R, Patel A, Jahan SA, Shepherd JE, Park K, et al. A review of the literature for whole-body FDG PET in the management of patients with melanoma. Q J Nucl Med 2000;44:153-67.
• 19 Stas M, Stroobants S, Dupont P, Gysen M, Hoe LV, Garmyn M, et al. 18-FDG PET scan in the staging of recurrent melanoma: Additional value and therapeutic impact. Melanoma Res 2002;12:479-90.
• 20 Fuster D, Chiang S, Johnson G, Schuchter LM, Zhuang H, Alavi A, et al. Is ¹⁸F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma? J Nucl Med 2004;45:1323-7.